903results about "Dragees" patented technology

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 5 kDa or more, the polymer matrix containing a hydrophobic polymer. The membrane polymer matrix includes from about 70 wt. % to about 99 wt. % of an ethylene vinyl acetate copolymer.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for improving obesity and metabolic syndrome and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 28 parts of radix astragali seu hedysari, 8 to 20 parts of radix codonopsis, 20 to 35 parts of rhizoma dioscoreae, 8 to 24 parts of semen lablab album, 6 to 20 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 20 to 35 parts of raw semen coicis, 3 to 10 parts of rhizoma pinelliae preparata, 6 to 15 parts of pericarpium citri reticulatae, 10 to 20 parts of poria cocos, 6 to 15 parts of rhizoma alismatis, 6 to 15 parts of raw liquorice root, 10 to 20 parts of semen hoveniae, 10 to 20 parts of lotus leaf and 8 to 15 parts of raw fructus crataegi. The composition has the effects of invigorating spleen, replenishing qi, resolving dampness and removing turbidity, can effectively control the weight gain of obese patients and improve the metabolic disorder condition of metabolic syndrome, is safe, effective and stable, has small side effects, and has very good research and development values.

The invention relates to the field of pharmaceutical preparations, and particularly discloses an amorphous-state tigorazan tablet and a preparation method thereof. The amorphous-state tigorazan tablet comprises a tablet and a coating material in a weight ratio of 100: (2-4), the tablet comprises the following raw materials: amorphous-state tigorazan, a carrier inclusion material, an excipient, a disintegrating agent, a lubricant and a flow aid, the dosage of the amorphous-state tigorazan is 20-30% of the total mass of all the raw materials of the tablet, and the dosage of the carrier inclusion material is 20-30% of the total mass of all the raw materials of the tablet. The weight ratio of the amorphous tigoran to the carrier inclusion material is 1: (0.80-1.15), and the carrier inclusion material is vitamin E polyethylene glycol succinate. The amorphous tigorazan tablet provided by the invention not only has higher solubility and dissolution rate, but also has higher stability and better hardness and friability, not only improves the bioavailability of drugs, but also avoids the use of organic solvents, simplifies the production process, reduces the risks of production safety and environmental protection, and is suitable for large-scale industrial production.

The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).

A unit dosage of an oral composition of an extract of Withania somnifera is disclosed. The extract of Withania somnifera includes total withanolides. The total withanolides includes withanolide glycosides and withanolide aglycones. The extract of Withania somnifera includes about 32% to about 38% by weight of the withanolide glycosides. Methods of preparing the extract of Withania somnifera are disclosed. Methods of treatment by administering the extract of Withania somnifera are disclosed.

The invention relates to the technical field of oral non-biological medicine preparations, in particular to an upatinib sustained release tablet and a preparation method thereof. The invention discloses a preparation method of an upatinib sustained-release tablet, and aims to solve the problem that the dissolution rate of the upatinib sustained-release tablet is unstable, namely, the upatinib sustained-release tablet can stably control the release of upatinib in different gastrointestinal tract environments through the synergistic cooperation of all the components of the upatinib sustained-release tablet, and the preparation method of the upatinib sustained-release tablet is relatively low in cost and easy to operate. The large-scale production is facilitated; the upatinib sustained release tablet comprises the following components in percentage by weight: 3.0%-3.5% of upatinib, 18%-19.50% of a pH regulator, 50%-55% of a filler, 17%-22% of an adhesive, 0.1%-1% of a flow aid, 1%-2% of a lubricant and 0.01%-10.9% of a coating material.

The invention belongs to the technical field of pharmaceutical preparations, relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and aims to overcome the technical defects of insufficient release behavior regulation and control precision and poor stability of an existing metformin hydrochloride sustained-release preparation. The metformin hydrochloride sustained-release tablet disclosed by the invention takes metformin hydrochloride as an effective component, is matched with sustained-release materials including hydroxypropyl methyl cellulose, propylene carbonate, zein, a filling agent, an adhesive and a lubricating agent, and can be selectively matched with a gastric-soluble film coating material. According to the invention, the stable release of the medicine is realized, the initial burst release phenomenon is avoided, meanwhile, the stability of the preparation is remarkably improved, and the good slow release performance can still be maintained after long-term storage.

The invention discloses afatinib tablets with high stability and rapid dissolution characteristics and a preparation method of the afatinib tablets, and belongs to the technical field of pharmaceutical preparations. In order to solve the problems that the dissolution rate is reduced and related substances are increased due to moisture absorption during the storage period of the existing afatinib tablets, afatinib dimaleate (crystal form A, D90 is 45-55m, and BET specific surface area is 2500-3000 m / kg) with a specific crystal form and particle size is adopted as a core and is compatible with an anhydrous crystal form auxiliary material (such as spray-dried mannitol), and the afatinib tablets are prepared into the afatinib tablets. Preparing a tablet core through dry granulation and a strict humidity control process, and then applying a damp-proof film coating. According to the scheme, the influence of water on the medicine is systematically blocked, the dissolution rate of the tablet in various dissolution media within 15 minutes is ensured to be greater than or equal to 85%, the dissolution rate is reduced by less than or equal to 5% after an accelerated test, the increase of related substances is obviously lower than that of a reference preparation, and the afatinib tablet with excellent dissolution performance and long-term stability is provided for clinic.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The present invention provides a tablet and a method for manufacturing a tablet that allows for easy formulation of coated tablets, even when calcium carbonate is used for coating the tablet. [Solution] A tablet coated with a coating layer, wherein the coating layer comprises calcium carbonate granules and a binder for binding the calcium carbonate granules together. The invention also provides a method for manufacturing a tablet coated with a coating layer, comprising a raw material preparation step of dispersing calcium carbonate granules and a binder for binding the calcium carbonate granules together in an aqueous medium to obtain a coating raw material, and a coating layer formation step of coating a tablet with the coating raw material.

The application discloses a trazodone hydrochloride sustained-release tablet and a preparation method thereof. The trazodone hydrochloride sustained-release tablet comprises the following components in mass: 20-50% of trazodone hydrochloride, 45-78% of a skeleton material and 1-6% of other medicinal adjuvants; and the skeleton material is a mixture of medium-viscosity polyoxyethylene, high-viscosity polyoxyethylene and polyethylene glycol. In the application, three-component materials are used as the skeleton tablet, the tablet release time, the sustained-release stability and the sustained-release amount are considered, the tablet volume is reduced, and the tablet preparation process is simplified.

A layered edible product includes a core and at least one active layer that is supported by the core. The at least one active layer can include a respective API. The edible product is configured to be placed against a mucosal surface of the oral cavity, which causes the respective API of the at least one active layer to enter the bloodstream through the mucosal surface. The core can be ingested gastrointestinally or can be dissolvable against the mucosal surface or both. The core can include a core API, or optionally the core can be API-free.

The present invention relates to formulations comprising dolutegravir or a pharmaceutically acceptable salt thereof, methods for making such formulations, and the use of such formulations in the treatment of HIV infection, particularly in the treatment of HIV infection in pediatric patients.

The invention discloses a pharmaceutical composition for improving liver dysfunction, the pharmaceutical composition comprises a tablet core and a coating film, the tablet core comprises 30-40 parts of mono-ammonium glycyrrhizinate (20-30 parts by weight of glycyrrhizin), 20-30 parts of glycine, 20-30 parts of methionine, 55-65 parts of a filler, 2-10 parts of a disintegrating agent, 1-10 parts of an adhesive and 1-10 parts of a lubricant, and the coating film is a gastric soluble film coating; wherein the filling agent is formed by compounding lactose, microcrystalline cellulose, calcium carbonate, calcium hydrophosphate and mannitol, the mass ratio of the lactose to the microcrystalline cellulose to the calcium carbonate to the calcium hydrophosphate to the mannitol is (1-24): (1-35): (1-25): (1-9): (1-9), and the pharmaceutical composition for improving liver dysfunction has good dissolution and stability.

The application belongs to the field of SOD preparation, and discloses a preparation method and device of SOD resistant to pepsin degradation, which comprises the following steps: S1 powder preparation: dissolving SOD fermentation pure liquid in a buffer solution with pH of 5.2-7.8, adding protective agent and tea yellow in sequence, stirring, filtering, and placing in a freeze dryer to prepare freeze-dried powder; S2 drying; S3 tabletting; S4, coating liquid preparation: dissolving wheat gliadin and soybean protein in a mixed solution prepared from water and ethanol with a volume ratio of 1:1, wherein the mass ratio of the wheat gliadin and the soybean protein is 0.5-1:1, adding glycerol, stirring for 20 min by using a magnetic stirrer, and ultrasonicating for 40 s; S5, coating: placing the tablets in a coating machine, setting air inlet volume, air inlet temperature, pan rotating speed, atomization rate, fan face pressure, and mortar flow, until the coating weight increases to 3%-10% in mass fraction and the coating thickness is 20-50 μm, and then drying and cooling. The prepared SOD is not easy to be photolyzed and can resist gastric acid degradation to ensure the complete activity of the SOD.

Solid pharmaceutical compositions containing an active pharmaceutical ingredient, such as a JAK inhibitor, and methods of treatment using such pharmaceutical compositions are described.

The present invention relates generally to improved formulations of 6- thioguanine (6-TG), their methods of preparation, and their use in treatment methods. The invention provides a pharmaceutical composition comprising 6-TG, and a polyethylene oxide polymer having a molecular weight of between about 900,000 g / mol and about 9,000,000 g / mol, their methods of preparation, and their use in methods for treating a disease or condition of the distal intestine that responds to 6-TG, wherein the 6-TG is released in the distal intestine.

The present disclosure relates to a method for preparing a veterinary medicament dosage using a 3D printer. The method comprises printing a plurality of layers comprising one or more active pharmaceutical ingredients (APIs) on the printing substrate, so that each layer comprising API is surrounded by layers comprising one or more taste masking agents, until a required dose of the one or more APIs is obtained. The disclosure also relates to a veterinary medicament dosage obtainable by the method.

The present invention relates to methods for treating anxiety associated with social anxiety disorder (SAD), also known as social phobia, by administering BNC210 or a salt or prodrug thereof.

The disclosure provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

The present invention can provide: a colon purgation tablet having a gel-forming coating layer containing an alginate as a main component, the gel-forming coating layer being introduced into an uncoated tablet containing an osmotic substance, the present invention relates to an uncoated tablet, and more particularly, to an uncoated tablet, such that the osmotic substance contained in the uncoated tablet disintegrates rapidly while preventing damage to gastric mucosa due to a physical collision between the tablet and the gastric mucosa, and thus provides an excellent intestinal cleansing effect. The colon purgation tablet according to the present invention can exhibit an excellent intestinal cleansing effect even at a small dose, and can further improve drug compliance by selectively miniaturizing the tablet or introducing an adhesive to improve a coating layer.

This application relates to a rifapentine-containing pharmaceutical composition and its preparation method. The rifapentine-containing granules are prepared by dry granulation, which reduces the content of impurities present in existing pharmaceutical compositions, especially the content of the genotoxic impurity 1-cyclopentan-4-nitrosopiperazine, thereby improving the safety and efficacy of the drug.

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.

The present invention provides, in part, compositions comprising a peptide that is larazotide or larazotide derivative, or salt thereof, contained within a matrix that provides for controlled release and sustained release formulations. The present invention contemplates that these compositions, formulations and methods can be useful for treating diseases and disorders of the small bowel.

This invention provides a method for treating a pulmonary arterial hypertension with reduced incident of side effect using a controlled release pharmaceutical composition of selexipag or its active metabolite, wherein the controlled release pharmaceutical composition of selexipag or its active metabolite following oral administration with an alcoholic beverage reduces incidence of at least one side effect associated with the selexipag or its active metabolite compared to the immediate-release dosage form comprising the same amount of the selexipag or active metabolite thereof.

Disclosed are pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and methylcobalamin. Also disclosed are methods of using the pharmaceutical compositions to treat patients suffering from Alzheimer's disease or Parkinson's disease.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention relates to a tablet comprising 6-((5-methyl-3-(6-methylpyridin-3- yl)isoxazol-4-yl)methoxy)-N-(tetrahydropyran-4-yl)pyridazine-3-carboxamide, to processes for its preparation, kits comprising it, and its use in medical treatment.

To provide crystalline forms of a C-C chemokine receptor type 4 antagonist.SOLUTION: There is provided the compound 2 - ((R) - 3 - (1 - (1 - ((R) - 1 - (2, 4-dichlorophenyl) ethyl) - 3 - (trifluoromethyl) - 1H - pyrazolor3, 4-b] pyrazin-6-yl) azetidin-3-yl) piperidin-1-yl) ethan-1-ol benzenesulfonate in crystalline form.SELECTED DRAWING: Figure 1